RMAT designation enables intensified FDA engagement and potential accelerated pathways, implying preliminary clinical evidence for RTx-015 despite absent peer-reviewed efficacy details, endpoints, and ...
Merck has initiated MALBEC, its phase 2b/3 clinical trial evaluating MK-8748 (also known as Tiespectus, EYE201) for the ...
Safety findings aligned with prior batoclimab experience, with no emergent safety liabilities reported across the phase 3 ...
A study from 7 institutions in Hong Kong reported that tapering of low-dose atropine before the drug was discontinued had ...
In this episode of the NeuroOp Guru in collaboration with Ophthalmology Times, host Andrew G. Lee, MD, is joined by Drew Carey, MD, to discuss pretreatment features associated with vision improvement ...
A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...
The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...
Pediatric candidates were predominantly complex, with severe corneal pathology and 6/11 eyes having preexisting glaucoma, ...
The US Food and Drug Administration has approved the extension of dosing intervals for Regeneron’s EYLEA HD (aflibercept) up ...
Renee Bovelle, MD: I am thrilled and humbled to be the first physician to lead OWL. It is a deep honor and a meaningful ...
A retrospective cohort of 15,045 Down syndrome patients with septal defects and 15,045 without enabled comparative risk ...
Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a move that would expand its presence in complement-mediated diseases, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results